Add BrightSurf on Google Email

NewYork-Presbyterian


Animal behavioral studies can mimic human behavior

Researchers have identified a human genetic alteration associated with anxiety-related behavior in both humans and mice, which can inform the development of new clinical strategies to treat anxiety disorders. The study used functional magnetic resonance imaging (fMRI) to reveal altered brain function in individuals with this abnormality.

SourceNewYork-Presbyterian·JournalScience·DateJan 14, 2010

World's first delivery of intra-arterial Avastin directly into brain tumor

Researchers successfully delivered high-dose chemotherapy to malignant brain tumors via intra-arterial Avastin, potentially avoiding common side effects of systemic chemotherapy. The innovative technique has shown promising results in early trials and may offer a new treatment option for patients with resistant brain tumors.

SourceNewYork-Presbyterian·JournalJournal of Experimental Therapeutics and Oncology·DateNov 17, 2009

NEJM study points to new era in hepatitis C treatment

A Phase IIb clinical trial shows that adding a hepatitis C protease inhibitor called telaprevir to standard therapy can significantly improve the chances of being cured, with a 67% cure rate in patients treated for 24 weeks. The treatment also reduces side effects and treatment duration compared to standard therapy alone.

SourceNewYork-Presbyterian·JournalNew England Journal of Medicine·DateJun 5, 2009

1 in 7 US teens is vitamin D deficient

A new study finds that more than half of African-American teens are vitamin D deficient, with girls at higher risk and overweight teens nearly double their normal-weight counterparts. The researchers highlight the importance of educating the public on vitamin D's benefits and consider national fortification strategies.

SourceNewYork-Presbyterian·JournalPEDIATRICS·DateMar 11, 2009

New approaches make retinal detachment highly treatable

Retinal detachment is a condition that affects about 10,000 Americans each year, putting vision loss or blindness at risk. NewYork-Presbyterian/Weill Cornell ophthalmologist Dr. Donald J. D'Amico highlights advanced surgical techniques that offer high probabilities of reattachment and visual improvement.

SourceNewYork-Presbyterian·JournalNew England Journal of Medicine·DateNov 26, 2008

HIV drug maraviroc effective for drug-resistant patients

The MOTIVATE trials show maraviroc significantly suppresses the virus at 48 weeks, increasing immune system T-cell counts and providing consistent clinical benefit for treatment-experienced patients with R5 HIV-virus infection. Maraviroc provides a valuable additional treatment option for a wide spectrum of treatment-experienced patients.

SourceNewYork-Presbyterian·JournalNew England Journal of Medicine·DateOct 1, 2008

Gender differences and heart disease

Researchers found that women derive less benefit from high-blood-pressure-lowering drugs than men for reducing left-ventricular hypertrophy, a marker for future heart disease. This may explain why women are at greater risk for heart disease later in life despite similar blood pressure reduction.

SourceNewYork-Presbyterian·JournalHYPERTENSION·DateJul 1, 2008